NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Kuehn Law , PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material... Read More

Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share Representing a total equity value of up to $1.1 billion including the CVR SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX) today announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate... Read More

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical... Read More

Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023 Completed candidate selection for SARS-CoV-2 and influenza programs, highlighting company’s antigen design capabilities Cash and cash equivalents, and short-term investments of $229.2 million at end 3Q 2023 SEATTLE, Nov. 14, 2023 (GLOBE... Read More

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one... Read More

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one... Read More

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor... Read More

Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV Initiation of Phase 2 Trial of IVX-A12 with topline interim results now expected by end 2023 Closed $67.8 million registered direct offering of common stock; extended cash runway into 2H 2025... Read More

In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) Data provide additional clinical evidence of potential differentiation on durability with company’s VLP platform technology Robust immune response against RSV-A observed in Phase 1b extension trial participants who were revaccinated... Read More

Phase 2 topline interim results expected in 1Q 2024 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision... Read More

SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that it has entered into a securities purchase agreement... Read More

IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults IVX-A12 was generally well tolerated with no vaccine-related SAEs First demonstration of hMPV vaccine immunogenicity in an older adult population No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12... Read More

IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at end 1Q 2023 SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against... Read More

FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 Cash and cash equivalents, restricted cash, and short-term investments of $219.4M at end 4Q 2022 SEATTLE, March 30, 2023... Read More

SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one... Read More

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced the U.S. Food and Drug Administration (FDA) has granted... Read More

Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform Phase 1 study of IVX-A12 (a bivalent of IVX-121 for RSV and IVX-241 for hMPV) progressing and on track for topline results in mid-2023 IVX-A12 Phase 2 initiation expected in 2H 2023 SEATTLE, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq:... Read More

COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which are being kept from work. This winter time, a terrible year for RSV as well as a potentially worse flu season could add insult to injury especially when one considers the fact that COVID-19 leaves some people with an impaired... Read More

In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults First clinical evidence of potential differentiation on durability with company’s VLP platform technology IVX-121... Read More

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one... Read More

Initiated a Phase 1 trial of Icosavax’s first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults IVX-A12 is the first bivalent vaccine candidate against both RSV and hMPV to reach clinical stage development Cash and cash equivalents, restricted cash, and short-term investments of $222.5M at end 3Q 2022 SEATTLE, Nov. 14, 2022 (GLOBE... Read More

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one... Read More

IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage Phase 1 topline interim results expected in mid-2023 Phase 2 initiation planned to follow in 2H 2023 Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against... Read More

Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human metapneumovirus (hMPV) VLP candidate, in 2H 2022 IVX-411 (COVID-19) drug product investigation confirmed molecule-specific instability of antigen component and no evidence of read-through to... Read More

Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs Now focused on a bivalent strategy for COVID-19 candidate development displaying computationally engineered RBD antigens; provides optionality as a potential future component of combination vaccines Additional corporate milestones across programs provided for 2H 2022 and 2023 Icosavax,... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the William Blair Biotech Focus Conference taking place from... Read More

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV +... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Jefferies Healthcare Conference taking place from June... Read More

Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen Topline, interim Phase 1/1b data for IVX-121 in RSV, including younger and older adults, expected in June Cash and restricted cash of $262.4M at end 1Q 2022 Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company... Read More

Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen Company anticipates topline, interim data for RSV lead program IVX-121 in 2Q 2022 Announced emerging program in flu, as part of strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults Reported... Read More

Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology; end-to-end drug product investigation underway Data indicate favorable preliminary reactogenicity profile Company remains on track for Phase 1/1b topline, interim data for lead program IVX-121 against respiratory syncytial virus (RSV) in... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen 42 nd Annual Health Care Conference taking place virtually from March 7-9, 2022. Adam Simpson, Chief Executive Officer of Icosavax, is scheduled to participate in the Infectious Disease... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS).... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in... Read More

Omega Funds , a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million , and included strong support from both new and existing limited... Read More

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Completed dosing in ongoing Phase 1/2 clinical trial for IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain - Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like... Read More

Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences. Details of the events are below: Jefferies London... Read More

Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen Raised $209.3 million in gross proceeds from an upsized IPO, funding operations through at least 2024 Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company... Read More

Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. “Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies,” said Adam Simpson, Chief... Read More

Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen, in healthy adults and older adults. Assuming favorable results from the IVX-121 Phase... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today acknowledged the sudden passing of Tadataka (Tachi) Yamada, M.D., co-founder and Chairman of the Board of Icosavax, who died unexpectedly on August 4, 2021. “It is with great... Read More

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase... Read More